Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Curevac N.V.
(NQ:
CVAC
)
3.200
-0.065 (-1.99%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Curevac N.V.
< Previous
1
2
3
Next >
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
April 22, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
April 21, 2022
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
April 11, 2022
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million...
From
CureVac
Via
AccessWire
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
March 30, 2022
- Phase 1 dose-escalation study started at clinical sites in the U.S. - Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
March 01, 2022
- The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics - CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
February 10, 2022
- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad...
From
CureVac
Via
AccessWire
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
January 17, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V.
January 13, 2022
BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für...
From
dievini Hopp BioTech holding GmbH & Co. KG
Via
AccessWire
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
November 19, 2021
- Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review - Nature publication of...
From
CureVac
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Death
Intellectual Property
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
November 18, 2021
TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
November 10, 2021
- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions - Expansion part of Phase 1 study fully recruited;...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
October 12, 2021
- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK - First-generation vaccine candidate, CVnCoV, to be withdrawn from...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
September 17, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
CureVac Streamlines European Network for mRNA Product Manufacturing
September 14, 2021
- CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands - Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
August 31, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
August 30, 2021
- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis - Further research aimed at optimizing mRNA...
From
CureVac
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Death
Intellectual Property
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
August 16, 2021
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update - Continuation of corporate transformation into commercial-ready biopharma company-...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
August 16, 2021
- Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
June 30, 2021
- Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for efficacy analysis; original strain almost completely absent - Statistical...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
June 30, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 30, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Announces Voting Results of General Meeting
June 25, 2021
TÜBINGEN, GERMANY andBOSTON, MA / ACCESSWIRE / June 25, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Provides Supervisory Board Update
June 23, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 23, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
June 16, 2021
- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent - At second interim analysis, statistical...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Appoints Klaus Edvardsen as Chief Development Officer
June 02, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
May 28, 2021
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases - Sequencing data to be made available in parallel with efficacy data given...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
May 26, 2021
- First-Generation COVID-19 vaccine program, CVnCoV - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
May 13, 2021
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK - CV2CoV mRNA shows high levels of antigen production in rat model - Fast onset of strong...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
April 19, 2021
- Rolling submission to accelerate time to marketing authorization of CVnCoV in Switzerland - Review process started with submission of first CVnCoV data package TÜBINGEN, GERMANY and BOSTON, MA /...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
April 15, 2021
- COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase...
From
CureVac
Via
AccessWire
Topics
Initial Public Offering
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.